Order Article Reprints

Choví-Trull M, Megías-Vericat JE, Bonanad-Boix S, Haya-Guaita S, Cid-Haro AR, Aguilar-Rodriguez M, Palanques-Pastor T, Garcia-Pellicer J, Poveda-Andrés JL. Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients. Hematology Reports. 2025; 17(5):53. https://doi.org/10.3390/hematolrep17050053

Choví-Trull, Maria, Juan Eduardo Megías-Vericat, Santiago Bonanad-Boix, Saturnino Haya-Guaita, Ana Rosa Cid-Haro, Marta Aguilar-Rodriguez, Tomás Palanques-Pastor, Javier Garcia-Pellicer, and Jose Luis Poveda-Andrés. 2025. "Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients" Hematology Reports 17, no. 5: 53. https://doi.org/10.3390/hematolrep17050053

Choví-Trull, M., Megías-Vericat, J. E., Bonanad-Boix, S., Haya-Guaita, S., Cid-Haro, A. R., Aguilar-Rodriguez, M., Palanques-Pastor, T., Garcia-Pellicer, J., & Poveda-Andrés, J. L. (2025). Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients. Hematology Reports, 17(5), 53. https://doi.org/10.3390/hematolrep17050053